open access

Vol 4, No 4 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-09-18
Get Citation

The impact of the benfothiamine treatment on the painful diabetic polyneuropathy

Przemysław Witek, Jacek Sieradzki
Diabetologia Praktyczna 2003;4(4):273-278.

open access

Vol 4, No 4 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-09-18

Abstract

INTRODUCTION. The painful diabetic polyneuropathy significantly decreases the quality of life, causes disability and is resistant to the treatment. All this brings the frustration to the suffering patients and the therapeutic team. Most of the clinical trials that tested number of drugs were disappointing because of the insufficient analgesic result or side effects. The aim of the study was to assess the efficacy of the treatment with lipophil form of vitamin B1 Benfothiamine (Benfogamma, Wörwag Pharma) in the painful diabetic polyneuropathy.
MATERIAL AND METHODS. We included 41 patients with type 2 diabetes and painful diabetic polyneuropathy into this study. All the patients scored at least 10 in the 20 point McGill scale. They were administered Benfothiamine 400 mg daily divided into 4 doses for 3 weeks. During the next 9 weeks they were given 150 mg daily in 3 doses. The severity of the pain, the sensation of vibration and touch, and the general well-being of the patients were assessed at the initial visit, after 3 and 12 weeks of treatment.
RESULTS. After 3 weeks of treatment the average threshold for the vibration sensation in the examined group on the right and the left foot improved from 3.47 to 3.74 (P = 0.0637) and from 3.60 to 4.03 (P = 0.0017), respectively. The severity of the pain decreased from 14.32 to 11.88 on the McGill scale (P < 0.0001). After 12 weeks, the further improvement was recorded in respect to the threshold of vibration sensation in the right and the left foot reaching 4.19 (P < 0.0001) and 4.38 (P < 0.0001), respectively. The severity of pain decreased to 8.80 points on the McGill scale (P < 0.0001). The general well-being of the patients improved substantially in 11 subjects, improved moderately in 12, slightly improved in 2, and remained unchanged in 6 diabetic patients. There was no a case of worsening in general well-being condition reported. After 12 weeks the significant improvement in the touch sensation was also observed as compared to the initial visit.
CONCLUSIONS. Benfothiamine has significantly improved the clinical course of the painful diabetic polyneuropathy.

Abstract

INTRODUCTION. The painful diabetic polyneuropathy significantly decreases the quality of life, causes disability and is resistant to the treatment. All this brings the frustration to the suffering patients and the therapeutic team. Most of the clinical trials that tested number of drugs were disappointing because of the insufficient analgesic result or side effects. The aim of the study was to assess the efficacy of the treatment with lipophil form of vitamin B1 Benfothiamine (Benfogamma, Wörwag Pharma) in the painful diabetic polyneuropathy.
MATERIAL AND METHODS. We included 41 patients with type 2 diabetes and painful diabetic polyneuropathy into this study. All the patients scored at least 10 in the 20 point McGill scale. They were administered Benfothiamine 400 mg daily divided into 4 doses for 3 weeks. During the next 9 weeks they were given 150 mg daily in 3 doses. The severity of the pain, the sensation of vibration and touch, and the general well-being of the patients were assessed at the initial visit, after 3 and 12 weeks of treatment.
RESULTS. After 3 weeks of treatment the average threshold for the vibration sensation in the examined group on the right and the left foot improved from 3.47 to 3.74 (P = 0.0637) and from 3.60 to 4.03 (P = 0.0017), respectively. The severity of the pain decreased from 14.32 to 11.88 on the McGill scale (P < 0.0001). After 12 weeks, the further improvement was recorded in respect to the threshold of vibration sensation in the right and the left foot reaching 4.19 (P < 0.0001) and 4.38 (P < 0.0001), respectively. The severity of pain decreased to 8.80 points on the McGill scale (P < 0.0001). The general well-being of the patients improved substantially in 11 subjects, improved moderately in 12, slightly improved in 2, and remained unchanged in 6 diabetic patients. There was no a case of worsening in general well-being condition reported. After 12 weeks the significant improvement in the touch sensation was also observed as compared to the initial visit.
CONCLUSIONS. Benfothiamine has significantly improved the clinical course of the painful diabetic polyneuropathy.
Get Citation

Keywords

diabetes mellitus; polyneuropathy; benfotiamine

About this article
Title

The impact of the benfothiamine treatment on the painful diabetic polyneuropathy

Journal

Clinical Diabetology

Issue

Vol 4, No 4 (2003): Practical Diabetology

Pages

273-278

Published online

2003-09-18

Bibliographic record

Diabetologia Praktyczna 2003;4(4):273-278.

Keywords

diabetes mellitus
polyneuropathy
benfotiamine

Authors

Przemysław Witek
Jacek Sieradzki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl